- 200 mg - Efavirenz;
- 600 mg - Efavirenz;
Without a Prescription
Efavirenz Capsules and Tablets, in combination with other antiretroviral agents, are prescribed for HIV-1 infection.
Efavirenz indication is based on two clinical trials of at least a year`s duration, which demonstrated prolonged suppression of
Efavirenz Capsules and Tablets recommended dose of is 600 mg orally, once daily, in combination with a protease inhibitor and/or nucleoside reverse transcriptase inhibitors (NRTIs).
It is recommended that Efavirenz Capsules and Tablets be taken on an empty stomach, preferably at bedtime. The increased Efavirenz concentrations observed following administration of Efavirenz Capsules and Tablets with food might lead to an increase in the frequency of adverse events. Dosing at bedtime may improve the tolerability of nervous system symptoms.
Concomitant Antiretroviral Therapy
Efavirenz Capsules and Tablets must be given in combination with other antiretroviral medications.
If Efavirenz Capsules and Tablets are co-administered with voriconazole, the voriconazole maintenance dose should be increased to 400 mg every 12 hours and the Efavirenz dose should be decreased to 300 mg once daily, using the Efavirenz Capsules formulation (three 100 mg capsules or one 200 mg and one 100 mg capsule).
Efavirenz Capsules and Tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product.
For some drugs, competition for CYP3A by Efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (eg, cardiac arrhythmias, prolonged sedation, or respiratory depression). Drugs that are contraindicated with Efavirenz are listed in Table 2.
Container of 30 capsules;